RAPID HIPPOCAMPAL SYNAPTIC POTENTIATION INDUCED BY KETAMINE METABOLITE (2R,6R)-HYDROXYNORKETAMINE PERSISTENTLY PRIMES SYNAPTIC PLASTICITY

Kyle A Brown,Musa I Ajibola,Todd D Gould

DOI: https://doi.org/10.1101/2024.10.18.619152

2024-10-22

Abstract:The pharmacologically active (R,S)-ketamine (ketamine) metabolite (2R,6R)-hydroxynorketamine (HNK) maintains ketamine's preclinical antidepressant profile without adverse effects. While hypotheses have been proposed to explain how ketamine and its metabolites initiate their antidepressant-relevant effects, it remains unclear how sustained therapeutic actions arise following drug elimination. To distinguish the physiological mechanisms involved in the rapid from sustained actions of HNK, we utilized extracellular electrophysiology combined with pharmacology to develop an in vitro hippocampal slice incubation model that exhibited pharmacological fidelity to the 1) rapid synaptic potentiation induced by HNK at the Schaffer collateral-CA1 (SC-CA1) synapse during bath-application to slices collected from mice, and 2) maintenance of metaplastic (priming) activity that lowered the threshold for N-methyl-D-aspartate receptor (NMDAR) activation-dependent long-term potentiation (LTP) hours after in vivo dosing. We then used this model to reveal novel druggable mechanisms engaged in HNK's temporally- sensitive antidepressant synaptic actions, finding that the induction of synaptic potentiation by HNK did not require NMDAR activity, but NMDAR activity was necessary to maintain synaptic priming. HNK required protein kinase A (PKA) activity to rapidly potentiate SC-CA1 neurotransmission to facilitate synaptic priming that persistently promoted LTP formation. HNK's rapid actions were blocked by inhibitors of adenylyl cyclase 1 (AC1), but not an AC5 inhibitor. We conclude that HNK rapidly potentiates SC-CA1 synaptic efficacy, which then stimulates priming mechanisms that persistently favor antidepressant-relevant plasticity. Targeting such priming mechanisms may be an effective antidepressant strategy, and using approaches such as our incubation model may aid in revealing novel pharmacological targets.

Pharmacology and Toxicology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore how ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) affects the efficacy of Schaffer collateral - CA1 (SC - CA1) synapses in the hippocampus and its plasticity mechanisms within a rapid and continuous time frame. Specifically, the research aims to:

1. **Distinguish the rapid and continuous action mechanisms of HNK**: Through an in - vitro hippocampal slice incubation model, researchers hope to distinguish the physiological mechanism differences between the rapid synaptic potentiation induced by HNK and the subsequent continuous synaptic plasticity (i.e., synaptogenesis).

2. **Reveal the action pathway of HNK**: The study found that HNK can rapidly enhance the transmission efficacy of SC - CA1 synapses. This process is independent of the activity of N - methyl - D - aspartate receptor (NMDAR), but the ability to maintain synaptogenesis requires the participation of NMDAR. In addition, the effect of HNK also depends on the activities of adenylate cyclase 1 (AC1) and protein kinase A (PKA), while the inhibitor of AC5 has no significant effect on the rapid effect of HNK.

3. **Develop new drug targets**: Through the above research, the authors believe that targeting these synaptogenesis mechanisms may be an effective antidepressant strategy, and using an incubation model similar to the one they developed is helpful to reveal new pharmacological targets.

In summary, the core objective of this paper is to analyze how HNK regulates synaptic function on different time scales through detailed electrophysiological experiments and technical means, thereby providing theoretical basis and experimental evidence for further developing safer and more effective antidepressant drugs.